Go offline with the Player FM app!
Ep 9. Phase 2 trial of dapirolizumab pegol in SLE
Manage episode 331798536 series 3341497
Prof Richard Furie (New York, USA) and Dr Anastasia Madenidou evaluate the Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. They discuss the unique dose-response relationship endpoint used in this trial and the plans for Phase 3.
Read the paper here
Registration is open for BSR's Annual Conference. As the UK's leading rheumatology event, we bring together over 2,000 delegates for three days of learning, knowledge sharing, networking and innovation. Book your ticket today!
Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.
43 episodes
Manage episode 331798536 series 3341497
Prof Richard Furie (New York, USA) and Dr Anastasia Madenidou evaluate the Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. They discuss the unique dose-response relationship endpoint used in this trial and the plans for Phase 3.
Read the paper here
Registration is open for BSR's Annual Conference. As the UK's leading rheumatology event, we bring together over 2,000 delegates for three days of learning, knowledge sharing, networking and innovation. Book your ticket today!
Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.
43 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.